ARTICLE | Company News
FDA lifts clinical hold on NeuroDerm's PD therapies
May 9, 2015 12:09 AM UTC
NeuroDerm Ltd. (NASDAQ:NDRM) gained $1.24 (11%) to $12.62 on Friday after FDA lifted a clinical hold on its Parkinson's disease candidates ND0612H and ND0612L. The company plans to begin U.S. clinical trials next half.
NeuroDerm said FDA placed the hold in June 2014 seeking additional information on the "accuracy, safety and compatibility" of the delivery device. ND0612H and ND0612L are high and low-dose formulations of liquid levodopa and carbidopa delivered continuously via a subcutaneous belt pump. ...